CA2888883A1 - Formulations of pyrimidinedione derivative compounds - Google Patents

Formulations of pyrimidinedione derivative compounds Download PDF

Info

Publication number
CA2888883A1
CA2888883A1 CA2888883A CA2888883A CA2888883A1 CA 2888883 A1 CA2888883 A1 CA 2888883A1 CA 2888883 A CA2888883 A CA 2888883A CA 2888883 A CA2888883 A CA 2888883A CA 2888883 A1 CA2888883 A1 CA 2888883A1
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
compound
salt
stabilizing
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2888883A
Other languages
English (en)
French (fr)
Inventor
Yanxia Li
Ping Gao
Yi Shi
Geoff G. Zhang
Yi Gao
Jianwei Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of CA2888883A1 publication Critical patent/CA2888883A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2888883A 2012-10-18 2013-10-18 Formulations of pyrimidinedione derivative compounds Abandoned CA2888883A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261715766P 2012-10-18 2012-10-18
US61/715,766 2012-10-18
PCT/US2013/065760 WO2014063101A1 (en) 2012-10-18 2013-10-18 Formulations of pyrimidinedione derivative compounds

Publications (1)

Publication Number Publication Date
CA2888883A1 true CA2888883A1 (en) 2014-04-24

Family

ID=49554481

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2888883A Abandoned CA2888883A1 (en) 2012-10-18 2013-10-18 Formulations of pyrimidinedione derivative compounds

Country Status (11)

Country Link
US (2) US9629841B2 (enExample)
EP (1) EP2908808A1 (enExample)
JP (2) JP6266635B2 (enExample)
CN (2) CN104853752B (enExample)
AU (1) AU2013330993B2 (enExample)
BR (1) BR112015008927A2 (enExample)
CA (1) CA2888883A1 (enExample)
EA (2) EA032913B1 (enExample)
MX (1) MX2015004973A (enExample)
SG (1) SG11201503051QA (enExample)
WO (1) WO2014063101A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
US20230119355A1 (en) * 2020-03-05 2023-04-20 Aurigene Discovery Technologies Limited Pharmaceutical compositions of a kinase inhibitor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4442257A1 (de) * 1994-11-28 1996-05-30 Beate Dr Podschun Sparsomycin
DK1083885T3 (da) 1998-06-11 2007-02-26 Pharmacia & Upjohn Co Llc Delavirdintabletformulering
OA12124A (en) 1999-12-23 2006-05-05 Pfizer Prod Inc Pharmmaceutical compositions providing enhanced drug concentrations.
GB0009522D0 (en) * 2000-04-19 2000-06-07 Smithkline Beecham Plc Composition
US6489363B2 (en) * 2000-10-11 2002-12-03 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
MX2007007342A (es) * 2004-12-15 2007-12-11 Elan Pharma Int Ltd Formulaciones de tacrolimus nanoparticuladas.
US20070082952A1 (en) * 2005-10-06 2007-04-12 Benjamin Eric J Pharmaceutical compositions, methods of preparation thereof, and methods of treatment
ES2368879T3 (es) * 2007-09-17 2011-11-23 Abbott Laboratories Pirimidinas antiinfecciosas y usos de las mismas.
EP2725015A1 (en) * 2007-09-17 2014-04-30 AbbVie Bahamas Ltd. Uracil or thymine derivative for treating hepatitis c
US20100166861A1 (en) * 2008-12-29 2010-07-01 Kelly Noel Lynch Pharmaceutical formulations of sevalamer, or salts thereof, and copovidone
AU2011223895A1 (en) * 2010-03-01 2012-09-13 Concert Pharmaceuticals Inc. Fluorouracil derivatives
SG2014011670A (en) * 2011-10-21 2014-10-30 Abbvie Inc Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv

Also Published As

Publication number Publication date
CN104853752B (zh) 2018-10-23
AU2013330993A1 (en) 2015-05-07
EA032913B1 (ru) 2019-08-30
CN104853752A (zh) 2015-08-19
SG11201503051QA (en) 2015-05-28
AU2013330993B2 (en) 2018-03-01
US20140113921A1 (en) 2014-04-24
US9629841B2 (en) 2017-04-25
EA201791354A2 (ru) 2017-11-30
JP6266635B2 (ja) 2018-01-24
JP2015534985A (ja) 2015-12-07
EA201590752A1 (ru) 2016-02-29
WO2014063101A1 (en) 2014-04-24
EA201791354A3 (ru) 2018-03-30
MX2015004973A (es) 2015-07-17
JP2018065858A (ja) 2018-04-26
US10201542B2 (en) 2019-02-12
EA028481B1 (ru) 2017-11-30
BR112015008927A2 (pt) 2017-07-04
EP2908808A1 (en) 2015-08-26
US20170181973A1 (en) 2017-06-29
CN109260207A (zh) 2019-01-25

Similar Documents

Publication Publication Date Title
NL1021857C2 (nl) Tamsulosinetabletten met een gewijzigde vrijgave.
JP5794650B2 (ja) 難溶性薬物の溶解性改善製剤
TWI660748B (zh) 用於口服投藥之包含非晶型托伐普坦（Ｔｏｌｖａｐｔａｎ）的懸浮液
JP2011516613A (ja) 好ましくはポサコナゾールおよびｈｐｍｃａｓを含む固体分散物中の経口用薬学的組成物
US9629805B2 (en) Stabilization of moisture-sensitive drugs
US8168221B2 (en) Composition 064
JP2008531509A (ja) 医薬品成分の改良された分散性を有する錠剤
US10201542B2 (en) Formulations of pyrimidinedione derivative compounds
WO2019219823A1 (en) Solid dispersion containing ritonavir
US20190091204A1 (en) Compositions of deferasirox
WO2022029799A1 (en) Solid dosage forms of palbociclib
WO2022153330A1 (en) Pharmaceutical compositions comprising acalabrutinib
CN112218626A (zh) 一种持续释放组合物及其制备方法
US20200046695A1 (en) Oral pharmaceutical composition of lurasidone and preparation thereof
US20130296325A1 (en) HIGH DRUG LOAD TABLET FORMULATION OF [(1R), 2S]-2-AMINOPROPIONIC ACID 2-[4-(4-FLUORO-2-METHYL-1H-INDOL-5-YLOXY)-5-METHYLPYRROLO[2,1-f][1,2,4]TRIAZIN-6-YLOXY]-1-METHYLETHYL ESTER
WO2022162687A1 (en) Pharmaceutical compositions comprising nilotinib
WO2009105049A1 (en) Oral tablet compositions containing nateglinide and surfactan ph adjusting agent
JPH09309828A (ja) 溶解を改善した薬剤組成物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20181015

FZDE Dead

Effective date: 20201019